Inflammatory bowel diseases (IBD) are the result of interactions between susceptibility and severity genes, the environment and the Innate and adaptive arms of the mucosal immune system. Results from several disease- and/or antibody-based genome-wide association studies have pointed to variants in several genes important in innate and adaptive immune responses related to Crohn's disease (CD) risk, protection and severity. Data generated over the last cycle of this PPG demonstrate that In CD and ulcerative colitis (UC), Tumor necrosis factor superfamily member-15 (TNFSF15) is associated with risk, protection and severity and toll like receptor (TLR)-8 is associated with risk and protection. We have shown an interaction between TLR8 signaling and expression of the TNFSF15 associated protein, TLIA. Activation of TLR8 signaling inhibits TLIA expression, which Is In contrast to its known function of inducing other pro- and anti-inflammatory molecules. However, there is great variability among controls and CD patients in the level of TLR8 as well the degree of TLR8 inhibition of TLIA surface and soluble mRNA expression that may be related to different variants in the TNFSF15 and TLRS genes. We have shown that TLIA is a central regulator of Th1 and Th17 mucosal inflammation in the mouse and in severe human CD, and that TLR8 is so far the only pathway capable of down regulating TLIA. Therefore, studying the functional consequences of IBD associated variants in these genes on in vitro TLIA expression and in vivo TLR8 regulation of TLIA-dependent and -independent mucosal inflammation is significant. This continuation of Project 2 is based on the following hypothesis: Patients with genetic variants in risk or severity associated haplotypes of TNFSF15 combined with those of TLR8 lead to enhanced expression of TLIA which is poorly inhibited when TLRS signaling is defective. Furthermore, patients with combinations of gene variants associated with high level TLIA expression and less TLRS inhibition have the greatest expression of TLIA in the mucosa and will have the most severe inflammation/clinical course. Specific Alms: 1) Determine the in vitro functional consequences of CD-related genetic variants on TLRS and TNFSF15; 2) Determine the in vivo effect of endogenous and exogenous ligand signaling of TLR8 In TLIA-dependent and -independent mucosal Inflammation; and 3) Determine the relationship of combinations of TNFSF15 and TLR8 genetic variants to clinical subtypes and how these variants relate to natural history.

Public Health Relevance

Inflammatory bowel diseases affect more than one million Americans and the incidence is rising. The work described In the program project proposal will further understanding of the causes of these diseases and aid in the development of patient-specific therapies.

Agency
National Institute of Health (NIH)
Institute
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Type
Research Program Projects (P01)
Project #
5P01DK046763-21
Application #
8566147
Study Section
Special Emphasis Panel (ZDK1-GRB-8 (O1))
Project Start
1997-09-30
Project End
2015-08-31
Budget Start
2012-09-01
Budget End
2013-08-31
Support Year
21
Fiscal Year
2012
Total Cost
$296,491
Indirect Cost
$121,947
Name
Cedars-Sinai Medical Center
Department
Type
DUNS #
075307785
City
Los Angeles
State
CA
Country
United States
Zip Code
90048
Brant, Steven R; Okou, David T; Simpson, Claire L et al. (2017) Genome-Wide Association Study Identifies African-Specific Susceptibility Loci in African Americans With Inflammatory Bowel Disease. Gastroenterology 152:206-217.e2
Volkmann, Elizabeth R; Hoffmann-Vold, Anna-Maria; Chang, Yu-Ling et al. (2017) Systemic sclerosis is associated with specific alterations in gastrointestinal microbiota in two independent cohorts. BMJ Open Gastroenterol 4:e000134
Gonsky, Rivkah; Fleshner, Phillip; Deem, Richard L et al. (2017) Association of Ribonuclease T2 Gene Polymorphisms With Decreased Expression and Clinical Characteristics of Severity in Crohn's Disease. Gastroenterology 153:219-232
Schwerd, T; Bryant, R V; Pandey, S et al. (2017) NOX1 loss-of-function genetic variants in patients with inflammatory bowel disease. Mucosal Immunol :
Zhang, Hong; Zheng, Libo; McGovern, Dermot P B et al. (2017) Myeloid ATG16L1 Facilitates Host-Bacteria Interactions in Maintaining Intestinal Homeostasis. J Immunol 198:2133-2146
Xu, Chunlan; Ghali, Sally; Wang, Jiani et al. (2017) CSA13 inhibits colitis-associated intestinal fibrosis via a formyl peptide receptor like-1 mediated HMG-CoA reductase pathway. Sci Rep 7:16351
Zhang, Hong; Zheng, Libo; Chen, Jeremy et al. (2017) The protection role of Atg16l1 in CD11c+dendritic cells in murine colitis. Immunobiology 222:831-841
Rivas, Manuel A; Graham, Daniel; Sulem, Patrick et al. (2016) A protein-truncating R179X variant in RNF186 confers protection against ulcerative colitis. Nat Commun 7:12342
Hoang-Yen Tran, D; Hoang-Ngoc Tran, D; Mattai, S A et al. (2016) Cathelicidin suppresses lipid accumulation and hepatic steatosis by inhibition of the CD36 receptor. Int J Obes (Lond) 40:1424-34
van der Gracht, Esmé; Zahner, Sonja; Kronenberg, Mitchell (2016) When Insult Is Added to Injury: Cross Talk between ILCs and Intestinal Epithelium in IBD. Mediators Inflamm 2016:9765238

Showing the most recent 10 out of 254 publications